Barclays analyst issues OVERWEIGHT recommendation for XERS on August 20, 2026 09:08AM ET. The previous analyst recommendation was Overweight.XERS was trading at $8.78 at issue of the analyst recommendation.The overall analyst consensus : BUY.Current analyst recommendations are : 9 - Buy, 1 - Hold recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport DateAnalyst CompanyActionPrevious GradeNew GradePrice when...
BTIG analyst issues BUY recommendation for LWAY on August 20, 2026 09:47AM ET. LWAY was trading...
BioLineRx Ltd. (BLRX) - This analysis reviews how the stock price reacted after the last 12...
CollPlant Biotechnologies Ltd. (CLGN) - This analysis reviews how the stock price reacted after the last...
111, Inc. (YI) - This analysis reviews how the stock price reacted after the last 12...
from BMO Capital issued a price target of $11.00 for CATX on 2026-08-18 20:21:01.The adjusted price target was set to $11.00.At the time of the announcement, CATX was trading at...
Patrick Trucchio from H.C. Wainwright issued a price target of $50.00 for ASMB on 2026-08-18 10:41:00.The adjusted price target was set to $50.00.At the time of the announcement, ASMB was...
from William Blair issued a price target of $24.00 for OOMA on 2026-08-17 13:42:00.The adjusted price target was set to $24.00.At the time of the announcement, OOMA was trading at...
Bobby Brooks from Northland Securities issued a price target of $37.00 for ISSC on 2026-08-17 13:14:56.The adjusted price target was set to $37.00.At the time of the announcement, ISSC was...
Martin Fan from Wedbush issued a price target of $45.00 for IMUX on 2026-08-17 11:18:16.The adjusted price target was set to $45.00.At the time of the announcement, IMUX was trading...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
